A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity

Journal of Rheumatology

Volumn 41, Issue 7, 2014, Pages 1282-1289

  Zhu, Junqing ^a   Zhou, Yi ^a   Chen, Xiaoguang ^a   Li, Juan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Anticitrullinated protein antibody; Extraarticular manifestations; Interstitial lung disease; Interstitial pulmonary fibrosis; Rheumatoid arthritis; Rheumatoid arthritis related pulmonary disease

Indexed keywords

BIOLOGICAL PRODUCT; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; METHOTREXATE; STEROID; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ARTICLE; ASIAN; CASE CONTROL STUDY; CAUCASIAN; DISEASE ASSOCIATION; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS RELATED PULMONARY DISEASE; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; ADULT; AGED; BLOOD; COMPLICATION; FEMALE; IMMUNOLOGY; LUNG DISEASES; MALE; META ANALYSIS; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; PEPTIDES, CYCLIC;

EID: 84903738000     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131341     Document Type: Article

References (34)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
2. Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol 2013;25:360-6.
3. Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. Rheumatology 2013;52:99-110.
4. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003;62:722-7. (Pubitemid 36886405)
5. Prete M, Racanelli V, Digiglio L, Vacca A, Dammacco F, Perosa F. Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev 2011;11:123-31.
6. Antin-Ozerkis D, Evans J, Rubinowitz A, Homer RJ, Matthay RA. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 2010;31:451-78.
7. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.
8. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
9. Szekanecz Z, Soos L, Szabo Z, Fekete A, Kapitany A, Vegvari A, et al. Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets? Clin Rev Allergy Immunol 2008;34:26-31.
10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CR, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
11. Kaore SN, Amane HS, Kaore NM. Citrulline: pharmacological perspectives and its role as an emerging biomarker in future. Fundam Clin Pharmacol 2013;27:35-50.
12. Giles JT, Danoff SK, Sokolove J, Wagner CA, Winchester R, Pappas DA, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 2013 May 28 (E-pub ahead of print).
13. Ruiz-Esquide V, Gomara MJ, Peinado VI, Gomez PJ, Barbera JA, Canete JD, et al. Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease? Clin Rheumatol 2012;31:1047-50.
14. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 2008;41:1074-7.
15. Aubart F, Crestani B, Nicaise-Roland P, Tubach F, Bollet C, Dawidowicz K, et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol 2011;38:979-82.
16. Jearn LH, Kim TY. Level of anticitrullinated peptide/protein antibody is not associated with lung diseases in rheumatoid arthritis. J Rheumatol 2012;39:1493-4.
17. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2005. [Internet. Accessed May 7, 2014.] Available from: www.ohri.ca/programs/clinical-epidemiology/oxford.asp
18. Zhu J, Qu H, Chen X, Wang H, Li J. Single nucleotide polymorphisms in the tumor necrosis factor-alpha gene promoter region alter the risk of psoriasis vulgaris and psoriatic arthritis: a meta-analysis. PLoS One 2013;8:e64376.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. (Pubitemid 34746062)
20. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. (Pubitemid 27387172)
21. Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 2012;106:1591-9.
22. Skare TL, Nakano I, Escuissiato DL, Batistetti R, Rodrigues TO, Silva MB. Pulmonary changes on high-resolution computed tomography of patients with rheumatoid arthritis and their association with clinical, demographic, serological and therapeutic variables. Rev Bras Reumatol 2011;51:325-30, 336-7.
23. Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 2008;27:511-3.
24. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63. (Pubitemid 30368225)
25. van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002;60:383-8. (Pubitemid 39089354)
26. Haye SM, Retamozo S, Vetorazzi L, Peano N, Diaz CP, Castanos MM, et al. [Anticitrullin antibody and the extra-articular manifestations in rheumatoid arthritis] [Article in Spanish]. Medicina (B Aires) 2013;73:21-5.
27. Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 2007;26:201-4. (Pubitemid 46020244)
28. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010;34:J258-65.
29. Linn-Rasker SP, van der Helm-van MA, van Gaalen FA, Kloppenburg M, de Vries RR, le Cessie S, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006;65:366-71. (Pubitemid 43268227)
30. Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 2012;7:e35296.
31. Thannickal VJ, Toews GB, White ES, Lynch JR, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004; 55:395-417. (Pubitemid 38316734)
32. Bringardner BD, Baran CP, Eubank TD, Marsh CB. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal 2008;10:287-301.
33. Rajasekaran BA, Shovlin D, Lord P, Kelly CA. Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis. Rheumatology 2001;40:1022-5.
34. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;63:1218-21. (Pubitemid 39273496)